|
|
Comparison of PAX1 gene DNA methylation detection and HPV-DNA typing in diagnosis and treatment of cervical precancerous lesions |
LI Jialu1,2, DONG Yuan2, WANG Yu3, ZHNAG Xiaoli1 |
1. Department of Obstetrics and Gynecology, the Third Medical Center, PLA General Hospital, Beijing 100039, China; 2. the Second Clinical Medical College of Southern Medical University, Guanghzou 510515, China; 3. Intelligent Computing Research Institute of Shandong Industrial Technology Research Institute, Jinan 272071, China |
|
|
Abstract Objective To analyze the characteristics and potential correlation between PAX1 gene methylation and HPV-DNA typing in the diagnosis and treatment of cervical precancerous lesions. Methods Patients who underwent liquid-based thin-layer cell testing (TCT) and human papillomavirus DNA (HPV-DNA) typing in the Department of Obstetrics and Gynecology of the Third Medical Center of PLA General Hospital from June 2021 to March 2022 were selected. A total of 194 patients with abnormal TCT results≥ atypical squamous cells of unknown significance (ASCUS) and/or HR-HPV positive and 130 patients with abnormal cervical tissue screening results who were referred for colposcopic biopsy were included in this study. TCT, HPV-DNA typing and quantitative PAX1 gene methylation were performed in all patients. Results Compared with CIN3+ (CIN3 and cervical cancer) and normal/cervicitis, CIN1 and CIN2, the methylation value of PAX1 gene in CIN3+ patients was significantly higher than that in normal, CIN1 and CIN2 patients. The methylation values of PAX1 gene from high to low were 18.21 (17.56, 18.66), 20.5 (20.07, 20.80), 20.41 (20.19, 20.72), 20.21 (19.77, 20,42), respectively. The TCT results showed that there were 45 patients with ASCUS, CIN2+ (CIN2, CIN3 and cervical cancer) compared with normal/CIN1, and the methylation value of PAX1 gene CIN2+ was significantly higher than that of normal/CIN1. The methylation values of PAX1 gene from high to low were 18.87 (17.80, 20.26) and 20.51 (20.19, 20.73), respectively. The methylation values of PAX1 gene in HPV16 and 18 positive patients were significantly higher than those in non-HPV16/18 positive patients. The methylation values of PAX1 gene in HPV16 positive and high-risk non-HPV16/18 positive patients were 19.10 (17.97, 19.88) and 20.33 (20.00, 20.50), respectively. The methylation levels of PAX1 gene in HPV18-positive and non-HPV16/18 positive patients were 19.49 (18.65, 20.31) and 20.33 (20.00, 20.50), respectively. However, there was no significant difference in the methylation value of PAX1 gene between single HPV16 positive patients and single HPV18 positive patients). Conclusions The methylation of PAX1 gene is related with the progression of cervical lesions and the type of HPV infection. The methylation values of PAX1 gene in patients with single HPV16 positive and single HPV18 positive are significantly higher than those in patients without HPV16/18 positive. In ASCUS patients, the methylation value of PAX1 gene in CIN2+ is significantly higher than that in normal /CIN1. It is suggested that PAX1 gene methylation detection is helpful for early identification of CIN3+ and ASCUS cervical high-grade lesions, and also helps to reduce the colposcopy referral rate of ASCUS patients.
|
Received: 11 July 2022
|
|
|
|
|
[1] |
王文文,邱丽华.DNA甲基化在卵巢癌中的研究进展[J].国际生殖健康/计划生育杂志, 2012, 31(4):312-315.
|
[2] |
Kristensen L S, Hansen L L. PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment[J]. Clin Chem, 2009,55(8):1471-1483.
|
[3] |
Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses[J]. Vaccine, 2012, 30(5):F55-70.
|
[4] |
Xu G, Liu Y, Zhang C, et al. Temporal and spatial expression of Sox9, Pax1, TGF-β1 and type I and II collagen in human intervertebral disc development[J]. Neurochirurgie, 2020, 66(3):168-173.
|
[5] |
Aliani A, Abid H, Mallali Y, et al. Association between gene promoter methylation and cervical cancer development: global distribution and a meta-analysis[J]. Cancer Epidemiol Biomarkers Prev, 2021,30(3):450-459.
|
[6] |
Lai H C, Ou Y C, Chen T C, et al. PAX1/SOX1 DNA methylation and cervical neoplasia detection: a taiwanese gynecologic oncology group(TGOG) study[J]. Cancer Med, 2014, 3(4): 1062-1074.
|
[7] |
Kong L Y, Du W, Wang L, et al. PAX1 methylation hallmarks promising accuracy for cervical cancer screening in asians: results from a meta-analysis[J]. Clin Lab, 2015, 61(10):1471-1479.
|
[8] |
Su P H, Lai H C, Huang R L, et al. Paired Box-1(PAX1) activates multiple phosphatases and inhibits kinase cascades in cervical cancer[J]. Sci Rep, 2019, 24, 9(1):9195.
|
[9] |
陈 飞, 尤志学,隋 龙,等.阴道镜应用的中国专家共识[J].中华妇产科杂志, 2020,55(7): 443-449.
|
[10] |
Cox J T, Schiffman M, Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy[J]. Am J Obstet Gynecol, 2003, 188(6):1406-1412.
|
[11] |
Basu P, Ponti A, Anttila A, et al. Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report[J]. Int J Cancer, 2018, 142(1):44-56.
|
[12] |
Jaisamrarn U, Castellsagué X, Garland S M, et al. Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study[J]. PLoS One, 2013, 8(11):e79260.
|
[13] |
Wentzensen N, Schiffman M, Palmer T, et al.Triage of HPV positive women in cervical cancer screening[J]. J Clin Virol, 2016, 76(Suppl 1):S49-55.
|
[14] |
Kelly H, Benavente Y, Pavon M A, et al. Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia(CIN2+): a systematic review and meta-analysis[J]. Br J Cancer, 2019, 121(11):954-965.
|
[15] |
Fang C, Wang S Y, Liou Y L, et al. The promising role of PAX1(aliases: HUP48, OFC2) gene methylation in cancer screening[J]. Mol Genet Genomic Med, 2019, 7(3):e506.
|
[16] |
Liu H, Meng X, Wang J. Real time quantitative methylation detection of PAX1 gene in cervical cancer screening[J]. Int J Gynecol Cancer, 2020, 30(10):1488-1492.
|
[17] |
Curry S J, Krist A H, Owens D K, et al. Screening for cervical cancer: US preventive services task force recommendation statement[J]. JAMA, 2018, 320(7):674-686.
|
[18] |
王文杰,余敏红,范世珍,等.人乳头瘤病毒(HPV)型别与SOX1和PAX1基因甲基化的相关性研究[J].中国实验诊断学,2020,24(8),1353-1356.
|
[19] |
Güzel C, Sten H J, Kok I M, et al. Molecular markers for cervical cancer screening[J]. Expert Rev Proteomics, 2021,18(8):675-691.
|
[20] |
Schmitz M, Wunsch K, Hoyer H, et al. Performance of a methylation specific real-time PCR assay as a triage test for HPV-positive women[J]. Clin Epigenet, 2017, 9:118.
|
|
|
|